Request Trial
shutterstock_189691379_turtix
turtix / Shutterstock.com
19 July 2022AmericasStaff writer

Federal Circuit affirms US university’s patent invalidations

Kidney test patents detect “natural phenomena” | Delaware court grants Natera and Eurofins summary judgments on ineligibility.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Battle over inhaler shape ends badly for Boehringer
21 May 2026   European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration.
Americas
Jones Day adds in-house biologics specialist to Boston office
20 May 2026   The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.
Americas
Kirkland & Ellis subject of alleged conflict in trade secrets clash
19 May 2026   In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

Battle over inhaler shape ends badly for Boehringer
Chinese medtech company fined by UPC over injunction breaches
Healthcare leads sweeping AI partnership in Singapore
Jones Day adds in-house biologics specialist to Boston office
Kirkland & Ellis subject of alleged conflict in trade secrets clash
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Orrick lands five-member M&A team in Paris
AbbVie’s trade secret suit against a Chinese rival gets green light